Parameet Kumar

Parameet Kumar is an accomplished scientist with extensive experience in antibody development and analytical methodologies, currently serving as a Senior Scientist II at MacroGenics, Inc., focusing on Antibody-Drug Conjugates and bispecific antibodies for cancer treatment. Previously, at Emergent BioSolutions, Parameet contributed to the development of Raxibacumab for anthrax treatment while overseeing validation data and documentation. At NOVAVAX INC, Parameet played a key role in assay development for SARS-CoV-2 vaccine analytical methods. Earlier work at Catalent Pharma Solutions involved developing cell-based assays for AAV gene therapy products. Academic positions include Assistant Professor at Uniformed Services University, where Parameet led research on non-coding RNA in cystic fibrosis, and previous postdoctoral fellowships at Johns Hopkins University, focusing on MicroRNAs in cystic fibrosis and cancer. Parameet holds a Ph.D. in Tuberculosis from All India Institute of Medical Sciences and advanced degrees in Biotechnology and Biology from Indian Institute of Technology, Roorkee, and Choudhary Charan Singh University, respectively.